NYSE:AZN
Astrazeneca P L C (AZN)
Financials 
Technical Analysis 
Jun 28, 2026, 12:00 amThis summary was created by AI, based on 9 opinions in the last 12 months.
AstraZeneca PLC (AZN-N) is exhibiting strong potential driven by its attractive valuation and substantial growth in their oncology business, corroborated by several experts. The stock has performed well, up 30% in the past 12 months, with expectations of reaching ambitious targets in 2024. Analysts point out the advanced pipeline and the company's strategic shift from defensive to growth positions, highlighting the stock's resilience in the healthcare sector. With a supportive 200-day moving average and a solid dividend yield, experts express confidence in its performance and future prospects, suggesting that current evaluations offer a favorable entry point for investors.
It is rare he has puts on in his fund, but he does on this one. They have declining revenues, but a huge amount of data coming out about the next 12 to 18 months. We have seen the tip of the iceberg. He still likes it. It is not terribly expensive and has a high dividend. Own it with others for diversification. M&A would not surprise him in big pharma soon.
Paul MacDonaldA diversified pharmaceutical, sort of shifting their business away from traditional fields. They are in decline right now on revenues. You want to be holding this along with Merck and Bristol-Myers. They have a very key study coming out, taking an immuno oncology drug and combining it with another immuno oncology drug. That is going to be a very key catalyst. Dividend yield of 4.5%. (Analysts’ price target is $34.)
Paul MacDonaldPfizer failed to acquire this company and the stock has dropped a lot. This trades at 14X earnings and has a great dividend yield and a great cash flow yield. Not expensive. Have some great things in their pipeline in the next little while, which will help the company out. Healthcare is a nice defensive area to be in if you are really worried about the stock market. (See Top Picks.)
Srikanth Iyer
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Has an impressive line of new products that should hit the market over the next 10 years, in cancer, diabetes and Alzheimer’s. They have underperformed for the last several years, and now is starting to turn the corner. Dividend yield of 4.28%. (Analysts’ Price Target is $38.)